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Randomized controlled trials (RCT) 
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Whole body extract immunotherapy (WBE) 
  
Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of 
developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect 
venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety 
of AIT in the management of insect venom allergy. 
 
Methods: We undertook a systematic review, which involved searching 15 international biomedical 
databases for published and unpublished evidence. Studies were independently screened and critically 
appraised using established instruments.  Data were descriptively summarized and, where possible meta-
analysed. 
 
Results: Our searches identified a total of 16,917 potentially eligible studies of which 17 satisfied our 
inclusion criteria. The available evidence was limited both in volume and quality, but suggested that 
venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting 
reactions (OR=0.08, 95% CI 0.03 to 0.26); meta-analysis showed that it also improved disease specific 
quality of life (risk difference=1.41, 95% CI 1.04 to 1.79).  Adverse effects were experienced in both the 
build-up and maintenance phases, but most were mild with no fatalities being reported.  The very limited 
evidence found on modeling cost-effectiveness suggested that VIT was likely to be cost-effective in those 
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Conclusions:  The limited available evidence suggested that VIT is effective in reducing severe 
subsequent systemic sting reactions and in improving disease specific quality of life.  VIT proved to be 
safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT 
needs to be established. 
 




Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a bee, wasp (i.e. 
paper wasp, yellow jacket or hornet) or ant (i.e. fire ants) sting. The risk of anaphylaxis to hymenoptera 
stings is greater in adults compared to children due to increased sting exposure, co-morbidities and 
concomitant medication use. Systemic reactions have been reported in up to 3% of adults, but in less than 
1% of children.1 2  
 
 
Symptoms range from large local reactions at the sting site to mild, moderate and severe systemic 
reactions. Mild systemic reactions usually manifest as generalized skin symptoms including flush, urticaria 
and angioedema. Typically, dizziness, dyspnea and nausea are examples of moderate reactions, while 
shock and loss of consciousness, or even cardiac or respiratory arrest all define a severe sting reaction. 
Seemingly mild reactions can progress into more severe reactions with little warning.  The fear of future 
severe systemic reactions usually greatly impairs quality of life. Around a quarter of fatalities from 
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Patients are advised to carry an emergency kit comprising of adrenaline (epinephrine), H1-antihistamines, 
and corticosteroids depending on the severity of their previous sting reaction(s).6 The only treatment that 
can potentially prevent further systemic sting reactions is venom immunotherapy (VIT). This may result 
in long-term clinical benefits and improved quality of life.7 8 However, despite these possible advantages, 
VIT is still not commonly used by physicians across all European countries.9  This is likely to reflect 
uncertainty about the clinical benefits and risks associated with use of VIT, uncertainties about the ethics 
of mounting further formal experimental studies when VIT is established practice in some countries, as 
well as the practical and economic implications associated with this treatment.  
 
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
guidelines for AIT. This systematic review is one of five inter-linked evidence syntheses that were 
undertaken in order to provide a state-of-the-art synopsis of the current evidence base in relation to 
evaluating AIT for the treatment of insect venom allergy, allergic rhinoconjunctivitis, food allergy, allergic 
asthma, and allergy prevention.10 11 12 13 14 These reviews will be used to contribute to and inform the 
formulation of key clinical recommendations for subsequent clinical practice guidelines.  
 
AIMS 
We assessed the effectiveness, safety and cost-effectiveness of VIT for the treatment of insect venom 
allergy. 
METHODS 
The detailed methods for this review have already been described in our published protocol. 10 Here, we 
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Search strategy 
A highly sensitive search strategy was developed, and validated study design filters were applied to retrieve 
all articles pertaining to the use of VIT for insect venom allergy from electronic bibliographic databases 
(Appendix 1). We conceptualized the searches to incorporate the four elements below as shown in Figure 
1.   
 
To retrieve systematic reviews, we used the systematic review filter developed at McMaster University 
Health Information Research Unit (HIRU) 
(http://hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx#Reviews).http://hiru.mcma
ster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx#Reviews). To retrieve randomized controlled 
trials (RCTs), we applied the Cochrane highly sensitive search strategy for identifying RCTs in 
MEDLINE.15  To retrieve non-randomized studies, i.e. controlled clinical trials (CCT), controlled before-
and-after (CBA) and interrupted time-series (ITS) studies, we used the Cochrane Effective Practice and 
Organisation of Care (EPOC) filter Version 2.4, available on request from the EPOC Group.16 17  To 




 We searched the following databases: Cochrane Library including, Cochrane Database of Systematic 
Reviews (CDSR), Database of Reviews of Effectiveness (DARE), CENTRAL (Trials), Methods Studies, 
Health Technology Assessments (HTA), Economic Evaluations Database (EED), MEDLINE  (OVID), 
Embase (OVID), CINAHL (Ebscohost), ISI Web of Science (Thomson Web of Knowledge), TRIP 
Database  (www.tripdatabase.com), Clinicaltrials.gov (NIH web), Clinicaltrialsregister.eu, Current 
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The search strategy was developed on OVID MEDLINE and then adapted for the other databases (see 
online supplement). In all cases, the databases were searched from inception to October 31, 2015.  
Additional references were included through searching the references cited by the identified studies, and 
unpublished work and research in progress was identified through discussion with experts in the field (see 
online supplement). We invited a panel of interdisciplinary external experts in the field from different 
regions to add to the list of included studies by identifying additional published and unpublished papers 
they are aware of and research in progress (Appendix 2). There were no language restrictions employed; 




We were interested in identifying studies conducted on patients of any age with a physician confirmed 
diagnosis of systemic sting reaction to a venom sting from bees, wasps (i.e. paper wasp, yellow jacket or 
hornet) or fire ants.   
 
Interventions of interest 
We considered VIT using different products (purified and non-purified, aqueous or depot IT) and 
different treatment protocols (conventional, cluster, rush and ultra-rush)18 administered through the 
subcutaneous (SCIT) or sublingual (SLIT) routes. 
 
Comparators 
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Study designs 
Systematic reviews of RCTs and RCTs were used to investigate effectiveness; health economic analyses 
were used to assess cost-effectiveness; and systematic reviews, RCTs and case series, with a minimum of 
300 patients, were used to assess safety.  We appraised the evidence by looking at higher levels of 
evidence such as systematic reviews and/or meta-analyses of RCTs, together with individual RCTs. 
However, as we were expecting to find only a limited number of RCTs, we also searched for and included 
quasi-RCTs (i.e. non-randomized controlled clinical trials (CCTs), controlled before and after (CBA) 
studies and interrupted time series (ITS) analyses). Given the high inherent risk of bias in making 
inferences from quasi-RCTs, our main conclusions in relation to effectiveness have been based on the 
findings of systematic reviews and RCTs; findings from the quasi-RCTs have only been used to guide 
suggestions on which areas need to be prioritized in future research.19  
 
Our exclusion criteria were: narrative reviews, discussion papers, non-research letters and editorials, 




 Our primary outcome measure of interest was short- and long-term efficacy assessed by tolerated 
sting challenge or field sting; long-term was defined as sustained clinical efficacy after 
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Secondary 
Our secondary outcome measures of interest were: 
 Assessment of disease specific quality of life 
 Safety as assessed by local and systemic reactions in accordance with the World Allergy 
Organization’s (WAO) grading system of side-effects20 21 
 Health economic analysis from the perspective of the health system/payer.  
 
Study selection 
All references were uploaded into the systematic review software DistillerSR and de-duplication was 
undertaken.  Study titles were independently checked by two reviewers (SD and HZ) according to the 
above selection criteria and categorized as included, not included or unsure. For those papers in the 
unsure category, we retrieved the abstract and re-categorized studies as above. Any discrepancies were 
resolved through discussion and, when necessary, a third reviewer arbitrated (AS). Full text copies of all 
potentially relevant studies were obtained and their eligibility for inclusion independently assessed. Studies 
that did not fulfil all of the inclusion criteria were excluded.  
 
Quality assessment strategy 
Quality assessments were independently carried out on each study by two reviewers (SD and HZ) using 
the relevant version of the Critical Appraisal Skills Programme (CASP) quality assessment tool for 
systematic reviews and health economic evaluations.22  We assessed the risk of bias of experimental 
studies using the criteria suggested by the Cochrane EPOC Group.23  RCTs, CCTs and CBAs were 
assessed for generation of allocation sequence, concealment of allocation, baseline outcome 
measurements, baseline characteristics, incomplete outcome data, blinding of outcome assessor, 
protection against contamination, selective outcome reporting and other risks of bias using the Cochrane 
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secular trends, the pre-specified shape of the intervention and if the intervention may have had an impact 
on data collection. These methodological assessments drew on the principles incorporated into the 
Cochrane EPOC guidelines for assessing intervention studies.25 We used the quality assessment form 
produced by the National Institute for Health and Care Excellence (NICE) to critically appraise case 
series.26 Any discrepancies were resolved by discussion or, if agreement could not be reached, by 
arbitration by the third reviewer (AS). 
 
Analysis, data synthesis and reporting 
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers (SD or AK and HZ), and any discrepancies were resolved. To minimize the risk of bias, 
reviewers were not involved in the quality appraisal of their own studies. 
 
A descriptive summary with data tables was produced to summarize the literature.  A narrative synthesis 
of the data was undertaken. Where possible, and appropriate, meta-analysis was undertaken using 
random-effects modeling using Stata (version 14).27    
 
Sensitivity and subgroup analyses, and assessment for publication bias 
We planned to undertake sensitivity analyses by comparing the summary estimates obtained by excluding 
studies judged to be at high risk of bias, but were unable to do this because of insufficient data.   
We planned to perform the following subgroup analyses, but were unable to undertake any of these due 
to insufficient data: 
 Children (5-11 years) versus adolescents (12-17 years) versus adults (≥18 years) 
 Conventional versus cluster versus rush versus ultra-rush protocols in SCIT 
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 Three versus five years of treatment 
 Different allergen doses (50µg versus 100µg versus 200µg of maintenance VIT) 
 Bee versus wasp versus fire ant venom 
 Patients with and without co-existent mast cell disorders.28  
 
We were unable to assess publication bias through the creation of funnel plots due to the small number 
of studies but were able to use Begg's rank correlation test.29 
 
Registration and reporting 
This review has been registered with the International Prospective Register of Systematic Reviews 
(PROSPERO): http://www.crd.york.ac.uk/prospero/.http://www.crd.york.ac.uk/prospero/.  The 
registration number is CRD42016035374. The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist was used to guide the reporting of the systematic review: 
http://www.prisma-statement.org/ (Appendix 3; see online supplement)      
   
RESULTS 
Overview of results 
Our searches identified a total of 16,950 potentially eligible studies of which 17 satisfied our eligibility 
criteria and were therefore included in this review (see Figure 2). The key characteristics and main 
findings of all included studies are detailed in Table 1 and the quality assessment of these studies is 
summarized in Tables 2-4.  The main findings are discussed in more detail below. 
Of the 17 included articles, five were systematic reviews;30 31 32 33 34 two of these systematic reviews 
undertook meta-analyses.29 33 The remaining 12 studies comprised of five RCTs,35 36 37 38 39 three CBAs 40 
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Four of the systematic reviews looked at the effectiveness of VIT,30 31 32 34 two at safety30 33 and one at 
cost-effectiveness.32 Two of the RCTs  looked at disease specific quality of life related issues in adults.36 37  
Two RCTs looked at children;38 39 one RCT studied both children and adults.34 One CBA solely focused 
on the safety of rush VIT protocol in adults,41 a second CBA looked at the long-term follow-up of 
children following VIT40 and the third  looked at the effect of VIT on anaphylactic sting reactions.42 
Finally, four case studies  investigated safety considerations.43 44 45 46 All of the primary  studies included in 
this review investigated SCIT. 
 
Effectiveness of VIT as judged by the risk of systemic sting reactions 
Twelve studies looked at the effectiveness of VIT. Four of these were systematic reviews, all of which 
were assessed to be of high quality.  30 31 32 34  The remaining studies were RCTs (n=5) 35 36 37 38 39 and CBAs 
(n=3). 40 41 42 
  
Systematic reviews 
Boyle et al. systematic review included six RCTs and one quasi-RCT.30  Three of the RCTs studied in this 
review also satisfied our eligibility criteria and these are therefore considered in detail below.35 38 39 The 
others were excluded because they did not meet our inclusion criteria. These included: Brown et al.  
(2003),47 which looked at the jack jumper ant, which was not an insect of interest in the protocol; Oude 
Elberink et al. (2006),48 which focussed on the burden of treatment of carriage of an adrenaline 
(epinephrine) auto-injector compared to VIT, which was not an outcome of interest; and Golden et al.  
(2009) and Severino et al.  (2008), which both included patients who had experienced large local reactions 
rather than a systemic reaction to an insect sting.49 50  
The primary outcome of interest in Boyle et al. was systemic reaction rates to a ‘field’ or a challenge sting 
in patients during the follow-up period of VIT treatment.30 The review concluded that VIT was effective 
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interval (CI) 0.03 to 0.28). They also found that VIT prevented large local reactions to a sting (RR=0.41, 
95% CI 0.24 to 0.69). 
 
The systematic review conducted by Dhami et al. on the management of anaphylaxis studied the 
effectiveness of VIT in preventing venom-triggered anaphylaxis.31 This review included four systematic 
reviews (Ross et al., 2010, Watanabe et al., 2010, Boyle et al., 2012 and Hockenhull et al., 2012) and 23 
individual studies of varying quality. It concluded that, although much of the evidence is of a low quality, 
the evidence did consistently suggest that VIT can significantly reduce the risk of systemic reactions in 
subsequent stings.  
 
The systematic review by Hockenhull et al. concluded that VIT reduced the likelihood of future systemic 
reactions.32 This review assessed the clinical and cost-effectiveness of a specific brand of VIT:  
Pharmalgen (ALK-Abelló). The original search strategy was to look at the effectiveness of Pharmalgen 
(ALK-Abelló) versus other non-VIT treatments, but this had to be modified as no studies were found 
matching the original objective; they therefore widened the criteria to include other forms of Pharmalgen 
VIT administration protocols. The quality of trials included in the review were overall judged to be at 
high risk of bias. The review concluded that although the evidence was poor, it suggested that 
Pharmalgen VIT reduced the risk of future systemic reactions.  
 
Watanabe et al. carried out a high quality systematic review looking at the effectiveness of VIT in patients 
who presented with a systemic reaction to insect stings.34 Four studies were included (Hunt et al., 1973, 
Schuberth et al.,   1983, Valentine et al., 1990 and Brown et al., 2003) and a meta-analysis was performed, 
based on the Schuberth et al. and Valentine et al.  studies, which demonstrated that there was a substantial 
reduction in the risk of systemic reactions occurring in children treated with VIT following an accidental 
sting (odds ratio (OR)=0.29  (95% CI 0.10 < OR < 0.87)). The other two studies were judged to be at 
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analysis. Overall, this systematic review concluded that VIT was effective and should be recommended 
for adults with systemic reactions and for children with moderate-to-severe reactions, but not for children 
who only experienced cutaneous manifestations of a systemic reaction.  
 
In summary, the evidence from these four systematic reviews suggests that VIT is effective in reducing 
subsequent systemic sting reactions in both children and adults; all four reviews have however highlighted 
the low quality of evidence that this conclusion is based on. 
 
RCTs 
Five RCTs (Hunt et al., Oude Elberink et al. 2002 and 2009, Schuberth et al.  and Valentine et al.) also 
focussed on the effectiveness of VIT.  35 36 37 38 39  
 
Hunt et al. was a single blind RCT of 59 patients aged 15-69 years investigating VIT versus whole body 
extract (WBE) immunotherapy versus placebo; it was judged to be at high risk of bias.35 After 6-10 weeks 
of treatment, patients were randomly selected for a sting challenge.  Of the 19 patients receiving VIT, 18 
were stung with only one (5%) systemic reaction. The WBE and placebo groups each had 20 patients 
from which 11 (64%) and 12 (58%) patients were stung, respectively. In both groups, there were seven 
systemic sting reactions (35%). There were significantly more systemic reactions to the sting challenge in 
the WBE and placebo groups when compared with the VIT group (P<0.01). There was no difference in 
effectiveness between the WBE and placebo group (P=1.0).  The authors concluded that VIT was 
superior to both WBE and placebo in preventing further systemic sting reactions and recommended the 
use of VIT to prevent life-threatening systemic sting reactions.  
 
The two Oude Elberink et al.  RCTs, which primarily looked at quality of life, also reported on re-sting 
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patients experienced a re-sting, one patient from the randomized control arm experienced a sting and 
developed a systemic reaction (1/38) which required use of an adrenaline auto-injector; one patient in the 
VIT group had a re-sting, but did not develop a systemic reaction. This patient was in the randomized 
VIT group.36 In the 2009 study, of 29 patients whose index sting reaction was confined to systemic 
cutaneous reactions, five patients experienced a field sting: three in the VIT group and two in the 
adrenaline auto-injector group. None of these five patients experienced a systemic sting reaction.37 
 
Schuberth et al.  and Valentine et al. both looked at children with non-life-threatening sting reactions.38 39 
Both of these trials were judged to be at moderate risk of bias. They randomized children to VIT or no 
VIT and studied systemic sting reactions to bees and wasps in those experiencing accidental stings.  
Schuberth et al, who looked at 181 children with systemic sting reactions limited to cutaneous 
manifestations found no statistical difference in the number of systemic sting reactions following an 
accidental sting in the VIT and no treatment group.36 They further found that no subsequent reaction was 
more severe than the original and in the no-VIT group of eight systemic reactions only one was as serious 
as the original. This led to their conclusion that children with primarily cutaneous manifestation to a sting 
were unlikely to experience a further systemic reaction following a re-sting. A total of 242 children were 
included in the Valentine et al.  study. Of 45 children who experienced 55 stings, only one child in the 
VIT group experienced a systemic reaction to a field sting (1.8% systemic reactions/sting) compared to 
seven systemic reactions from 68 stings in 61 children who did not receive VIT (10.3% systemic 
reactions/sting) over a period of four years (RR=0.21, 95% CI 0.03 to 1.66, P=0.14).37 Both studies 
concluded that VIT is not indicated in children with cutaneous manifestations only. 
 
CBAs 
The CBAs by Golden, Pasaoglu and Reisman et al.  were all judged to be at moderate risk of bias.40 41 42 
Golden et al assessed the long-term effectiveness of VIT compared to no VIT in preventing systemic 
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prolonged benefit in the treatment group as the VIT group experienced less systemic sting reactions (2 of 
64 patients, or 3%) than the untreated patients (19 of 111 patients, or 17%; P=0.007).40 This study 
suggested VIT was effective in children with moderate-to-severe reactions, but that VIT was not 
recommended in children who experienced mild reactions.   
 
In contrast, the CBA by Pasaoglu et al. looked at the effectiveness of a seven day rush protocol of VIT in 
18 patients.41 Seven received bee VIT, seven yellow jacket VIT and four were controls. Of the 14 patients 
who received VIT, two experienced accidental stings (including a bee keeper who had multiple stings).  
No systemic sting reactions occurred. They concluded that a seven day rush protocol is effective. 
 
The CBA by Reisman et al. looked at children and adults with anaphylaxis to stings from honeybee or 
yellow jacket or bald-faced hornets or paper wasps.42 They looked at three groups and their subsequent 
reactions to accidental stings over a seven year period: those who had VIT, those who started VIT, but 
stopped prematurely and those without VIT. The group which took VIT for the recommended duration 
(mean 34 months) had 87 re-stings with only two systemic reactions (1%). The group which stopped VIT 
prematurely (duration of VIT one month to 6.5 years) experienced 61 re-stings with 11 systemic reactions 
(17%). The group with no-VIT experienced 40 re-stings with 14 systemic reactions (35%). They 
concluded that VIT was almost 100% protective against subsequent sting triggered anaphylaxis. 
 
Meta-analysis of the Reisman and Golden et al. studies demonstrated an overall substantial protective 
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Impact on disease specific quality of life 
Systematic reviews 
The systematic review by Boyle et al. drew on two RCTs by Oude Elberink et al. 200648 and 2009,36 the 
latter of which is also included in this review and discussed below.  This systematic review found that VIT 
was associated with a significant improvement in disease specific quality of life after one year of VIT 
(RR=7.11, 95% CI 3.02 to 16.71).30 
 
RCTs 
Two RCTs (Oude Elberink et al., 2002 and Oude Elberink et al., 2009) assessed the impact of VIT on 
disease specific quality of life measured using the Vespid allergy Quality of Life Questionnaire (VQLQ).36 
37 Both  of these studies looked at patients allergic to yellow jackets. The Oude Elberink et al. (2009) RCT 
study looked at the impact on disease specific quality of life in patients who had experienced only 
cutaneous manifestations of a systemic reaction; patients were randomized to VIT or an adrenaline auto-
injector. The VQLQ score of patients in the VIT arm improved significantly (mean change 0.83 (SD 
0.87); P<0.01), in contrast to patients randomized to an adrenaline auto-injector whose scores 
deteriorated (mean change -0.42 (SD 0.64)), resulting in an overall risk difference of 1.25 (95% CI 0.63 to 
1.87). The study suggested that all adults, including those who only had dermal reactions as a systemic 
allergic reaction to yellow jacket stings, should be considered for VIT and sole treatment with an 
adrenaline auto-injector should be avoided.37  
A similar earlier RCT (2002) by the same research team looked at disease specific quality of life in patients 
who had experienced a systemic reaction after a yellow jacket sting that was not solely confined to the 
skin.36 The findings of this study were confirmed in their 2009 study, whereby there was a clinically 
relevant improvement in disease specific quality of life in patients treated with VIT. The mean change in 
VQLQ score in the group randomized to VIT was 1.07 (95% CI, 0.68 to 1.46), and this improvement was 
also statistically significant (P <0.0001) compared with that seen in the group randomized to the 
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between the two groups of 1.51 (95% CI, 1.04 to 1.98). Of every three patients treated with VIT, two 
patients experienced a clinically relevant important improvement in their disease specific quality of life.  
Overall, it was found that 72% of patients benefited from VIT, this corresponding to a number needed to 
treat (NNT) of 1.4. Meta-analysis of these studies demonstrated an improvement in disease specific 
quality of life (1.41, 95% CI 1.04 to 1.79) (see Figure 4).  The Begg test (P=0.317) showed no evidence of 




The review by Boyle et al. assessed the safety of VIT, six trials reported on this outcome. They concluded 
that VIT carries a small but significant risk of systemic reactions (RR=8.16; 95% CI 1.53 to 43.46).30 They 
further looked at 11 observational studies for safety and found that systemic adverse events occurred in 
14.2% of participants treated with bee venom VIT and 2.8% of those treated with wasp venom VIT. 
 
The systematic review by Park et al., which was assessed as of a low quality, looked at identifying the 
frequency and types of adverse events associated with different types of bee venom therapy; in doing so 
they included VIT, but also acupuncture.32 It included 145 studies consisting of 20 RCTs, 79 audits and 
cohort studies, 33 single case studies and 13 case series. Two RCTs on VIT were included (Oude 
Elberink et al. 2002 and 2006), one of which we have included in this review (2002), and 63 case 
series/cohort studies. From 46 VIT case series/cohort studies, the median incidence of adverse events 
was 28.9%.  Of these, 50.4% had systemic reactions and 10.0% large local reactions. 35.8% showed just 
local reactions and 3.9% had “other” reactions.  
RCTs 
Of the RCTs included in this review two reported very limited information on safety considerations of 
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CBAs 
The CBA conducted by Pasaoglu et al. evaluated the safety of a rush VIT protocol lasting on average 
seven days and monitored for local and systemic reactions during both the induction and maintenance 
phases of VIT treatment over a one year period. The study concluded that rush VIT was safe and 
associated with a low risk of systemic reactions (four systemic reactions from a total of 469 injections, this 
equating to a 0.85% risk per total number of injections) and that this treatment approach could therefore 
be considered for patients requiring rapid protection such as those with a high risk of subsequent stings 
(e.g. bee keepers and their families). The risk of systemic reaction to VIT was related to the type of 
venom used with vespid venom being better tolerated than bee venom.41 
 
Case series 
Four large case series (i.e. Brehler, Mosbech, Ruëff and Stoevesandt et al.) met our eligibility criteria. The 
Brehler et al. study looked at the safety implication of shortening the 7-9 day rush protocol to two days as 
well as increasing the initial dose of venom administered. No anaphylactic reactions were seen in 1055 
VIT treatments in 966 patients; most adverse events were mild and none needed treatment with 
adrenaline. Overall, they concluded the two day rush protocol is safe and the risk of systemic reactions is 
rare when the number of injections administered is reduced from 20 subcutaneous injections to nine.43 
 
The Mosbech et al. case series included 840 patients, was conducted in 10 European countries and 
assessed the safety of VIT in both the build-up and maintenance phases in patients allergic to honey bees, 
wasps and paper wasps.46 Treatment protocols were not standardised across centres and conventional, 
rush and cluster protocols were used. 782 patients received VIT with one venom and 58 with two 
venoms respectively. A total of 26,601 injections were administered and 299 systemic side-effects 
occurred (1.2% of injections). Most of these reactions were mild with only one-third needing treatment. 
One patient required adrenaline. Adverse events were more frequent during the dose-increase phase than 
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in an increase in adverse events. These included female gender, rapid dose-increase regimens, and VIT 
with bee-venom extract. They concluded that systemic side-effects may occur in up to 20% of patients, 
but are usually mild.  
 
The Ruëff et al. case series looked at measuring the severity of reactions according to the Ring and 
Meßmer51 tool during the build-up phase of VIT, which required emergency intervention. They evaluated 
conventional, rush and ultra-rush protocols for bee and vespid immunotherapy. The study identified a 
number of risk factors that led to a higher frequency of adverse events requiring emergency intervention 
during VIT; these included bee venom immunotherapy and using rush and ultra-rush protocols.  The 
authors concluded that patients receiving bee VIT warrant closer monitoring than those patients receiving 
VIT to other insects.44  
 
Stoevesandt et al. looked at the incidence of systemic reactions during 818 build-up cycles (rush five day 
or ultra-rush three day inpatient treatment protocol) and the severity of VIT related anaphylaxis was 
graded according to the WAO classification system.20 The data from this study indicated that rush 
protocols were safe with very low numbers of patients suffering from moderate-to-severe systemic 
anaphylaxis based on the WAO classification system (i.e. 673 (82.3%) of 818 documented build-up cycles 
were tolerated without complications).  However, the authors acknowledged that due to low numbers of 
moderate-to-severe anaphylaxis reactions (0.8% of patients in the total cohort), robust statistical 
conclusions could not be drawn.45  
 
Health economic analysis 
We found only one study, the review by Hockenhull et al., that looked at the economic evaluation of VIT 
– a modeling study looking at the cost-effectiveness of VIT for the treatment of bee and wasp venom 
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auto-injectors versus high dose H1-antihistamines plus adrenaline auto-injectors and avoidance advice 
only. It found that VIT was not cost-effective in the general population (incremental cost-effectiveness 
ratio (ICERs) of £18 million and £7.6 million per quality adjusted life year (QALY) against high dose H1-
antihistamines plus AAI and avoidance advice only, respectively), but more effective than other treatment 
options and cost saving in patients likely to be stung more than five times per year such as bee keepers. 
This one study, despite the fact that it was based largely on expert opinion and plausible assumptions, 
resulted in the suggestion that VIT for bee and wasp venom allergy is only cost-effective from a UK 
National Health Service (NHS) perspective for very high risk groups likely to be exposed to multiple 
exposures to venom per year such as bee keepers. The modelling analysis suggests plausible ranges of 
exposure to such events to qualify a patient as a member of a high risk group and explores a wide range 
of sensitivity and scenario analyses to demonstrate the robustness of its findings.   
 
We were unable to find any primary studies assessing the cost-effectiveness of VIT for venom allergy. 
 
DISCUSSION 
Statement of principal findings 
This systematic review has found a modest body of evidence of moderate quality which suggests that VIT 
is effective in reducing subsequent severe systemic sting reactions in both children and adults and that 
this treatment modality can have a significant beneficial impact on disease specific quality of life when 
compared with carrying an adrenaline auto-injector The available data on the safety of VIT suggests that 
although adverse events occurred during both the build-up and maintenance phases, the vast majority 
were relatively mild with adrenaline only being needed very infrequently and – importantly – no fatalities 
being recorded.  We found no primary evidence on the cost-effectiveness of VIT; the one modelling 
study found that VIT would be cost-effective in high risk groups or if disease specific quality of life was 
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Strengths and limitations 
There are a number of strengths to this systematic review.  In particular, we searched a broad array of 
databases for published and in progress research, and also consulted with a panel of international experts 
in an attempt to identify unpublished evidence.  Furthermore, our systematic review was conducted 
according to a pre-defined, published protocol with no deviations from this.10  
 
The limitations of this review also need to be considered.  Key here were the limited number of studies 
identified, despite the fact that we also included CBAs.  The review is further limited by the low quality of 
the primary studies. Furthermore, two of the RCTs included in this systematic review (i.e. Valentine and 
Schuberth) excluded patients who had life-threatening systemic reactions to the initial sting – the group of 
patients who would be most likely to benefit from VIT.37 38 Furthermore, it should be noted that in both 
of these studies, the definitive identification of the culprit insect responsible for the accidental sting was 
not possible. Thus, whether the child was stung by the insect responsible for the index sting which 
resulted in a systemic reaction was unknown. This is in contrast to the Hunt trial in which patients were 
sting challenged by the insect they were known to be allergic to.36 As this review did not include the jack 
jumper species of ants the double-blind placebo controlled RCT by Brown et al. (2003) could not be 
included in this review.46 This study concluded that VIT significantly reduces the risk of serious 
subsequent sting reactions from the jack jumper ant (P<0.0001). Only one study assessed the cost-
effectiveness of VIT and this was limited to looking only at one product and based on an economic 
modeling analysis.31 Finally, as with any systematic review there is the possibility that we missed some 
studies.  
Interpreting the results of this review in the context of the wider literature 
In undertaking this systematic review, we sought to identify all relevant previous systematic reviews. Our 
findings are broadly in accordance with these previous reviews, namely that VIT is beneficial, but that this 
judgement is limited by the paucity and quality of the relevant evidence base. Guidelines for the long term 
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moderate to severe systemic reactions.52 53 In agreement with our findings, VIT is not recommended in 
children whose index reaction was confined to cutaneous manifestations. SLIT remains an experimental 
treatment in VIT; no SLIT studies satisfied our eligibility criteria. 
 
Implications for policy, practice and research 
The results of our review indicate that people who experience moderate-to-severe systemic reactions to 
venom are likely to benefit from treatment with VIT.  This benefit consists of a reduction in the 
frequency and severity of subsequent systemic reactions following future stings and/or a clinically 
relevant improvement in disease specific quality of life. We found very limited evidence on the cost-
effectiveness of VIT for venom allergy which thus needs to be interpreted cautiously; the available 
evidence, from a single economic modeling study, indicated that VIT is likely to be cost-effective in 
patients at high risk of future sting reactions and/or if quality of life is impaired.   
 
Given the paucity of high quality evidence uncovered, consideration needs to be given to undertaking 
high quality studies investigating the effectiveness and cost-effectiveness of VIT.  RCTs in both adults 
and children would be of interest, but due to the risk of life-threatening reactions in untreated patients, 
RCTs may not be considered ethical by some clinicians and furthermore they may not be approved by 
some ethics committees. It seems unlikely therefore that there will be further placebo controlled trials of 
VIT preparations in the foreseeable future.  As for VIT regimens, at present many protocols for VIT are 
used discretionally at treatment centers with varying build-up and maintenance doses with no defined 
duration of treatment. These protocols vary from conventional (12 weeks) to one day ultra-rush protocols 
during the build-up phase. Time taken to reach the maintenance dose will be dependent on the build-up 
phase and varies across centers.  Trials should therefore be considered comparing different VIT regimens, 
doses and durations of VIT. Whether trials of SLIT for venom allergy are indicated is debated.48 54 More 
standard reporting of VIT associated adverse events is needed in order to allow comparison across 
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Conclusions 
The limited available evidence suggests that VIT is effective in reducing subsequent severe systemic sting 
reactions and in improving disease specific quality of life. VIT proved to be safe and no fatalities were 
recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established. 
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significantly 
greater than the 
venom treated 
group, P<0.01. 
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the index reaction. 
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SRs. 
Conclude that 
using VIT for 
children with mild 
systemic reactions 
is not justified but 
should be used in 
those with life 
threatening 
reactions   
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from 3.34 to 2.9, 
(P<.003). Mean 
change in VIT 
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CI 0.68 to 1.46), 
mean change in 
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significantly in the 
NR -Epi group 
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Figure 3: Meta-analysis of CBA studies investigating the effectiveness of VIT on risk of systemic 
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